Alkermes Gets Alcohol Drug Rights From Cephalon

12/1/08

Cambridge, MA-based Alkermes is getting full commercial rights to a drug for alcohol dependence after its partner, Frazer, PA-based Cephalon, relinquished its share of the product. Alkermes (NASDAQ: ALKS) will receive an $11 million payment from Cephalon to cover estimated losses from commercializing naltrexone for extended release injectable suspension (Vivitrol), while Alkermes will pay Cephalon about $16 million for manufacturing equipment. For fiscal 2009, Alkermes expects the drug to generate $5 million to $8 million in sales.

By posting a comment, you agree to our terms and conditions.